IDXX vs. ALC, HUM, GEHC, CNC, HLN, MRNA, TAK, IQV, COR, and DXCM
Should you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include Alcon (ALC), Humana (HUM), GE HealthCare Technologies (GEHC), Centene (CNC), Haleon (HLN), Moderna (MRNA), Takeda Pharmaceutical (TAK), IQVIA (IQV), Cencora (COR), and DexCom (DXCM). These companies are all part of the "medical" sector.
Alcon (NYSE:ALC) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership.
Alcon presently has a consensus target price of $91.22, indicating a potential upside of 16.34%. IDEXX Laboratories has a consensus target price of $580.88, indicating a potential upside of 22.10%. Given Alcon's stronger consensus rating and higher probable upside, analysts clearly believe IDEXX Laboratories is more favorable than Alcon.
Alcon has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.
Alcon has higher revenue and earnings than IDEXX Laboratories. Alcon is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
IDEXX Laboratories received 351 more outperform votes than Alcon when rated by MarketBeat users. Likewise, 72.68% of users gave IDEXX Laboratories an outperform vote while only 60.92% of users gave Alcon an outperform vote.
53.9% of Alcon shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 1.5% of Alcon shares are held by insiders. Comparatively, 2.1% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, IDEXX Laboratories had 22 more articles in the media than Alcon. MarketBeat recorded 30 mentions for IDEXX Laboratories and 8 mentions for Alcon. Alcon's average media sentiment score of 0.47 beat IDEXX Laboratories' score of 0.22 indicating that IDEXX Laboratories is being referred to more favorably in the news media.
IDEXX Laboratories has a net margin of 23.08% compared to IDEXX Laboratories' net margin of 10.30%. Alcon's return on equity of 71.66% beat IDEXX Laboratories' return on equity.
Summary
IDEXX Laboratories beats Alcon on 15 of the 18 factors compared between the two stocks.
Get IDEXX Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IDEXX Laboratories Competitors List
Related Companies and Tools
